Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
KRAS G13D
i
Other names:
KRAS, KRAS1, KRAS2, Kirsten rat sarcoma viral oncogene homolog
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
3845
Related biomarkers:
Expression
Mutation
CNA
Others
‹
KRAS amplification (7)
KRAS deletion (1)
KRAS amplification (7)
KRAS deletion (1)
›
Related tests:
therascreen® KRAS RGQ PCR Kit (5)
therascreen® KRAS RGQ PCR Kit (5)
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
KRAS G13D
Colorectal Cancer
KRAS G13D
Colorectal Cancer
panitumumab
Resistant: A2 - Guideline
panitumumab
Resistant
:
A2
panitumumab
Resistant: A2 - Guideline
panitumumab
Resistant
:
A2
KRAS G13D
Colorectal Cancer
KRAS G13D
Colorectal Cancer
cetuximab
Resistant: A2 - Guideline
cetuximab
Resistant
:
A2
cetuximab
Resistant: A2 - Guideline
cetuximab
Resistant
:
A2
KRAS G13D
Hepatocellular Cancer
KRAS G13D
Hepatocellular Cancer
sorafenib + BAY86-9766
Sensitive: C3 – Early Trials
sorafenib + BAY86-9766
Sensitive
:
C3
sorafenib + BAY86-9766
Sensitive: C3 – Early Trials
sorafenib + BAY86-9766
Sensitive
:
C3
KRAS G13D
Non Small Cell Lung Cancer
KRAS G13D
Non Small Cell Lung Cancer
erlotinib
Resistant: C3 – Early Trials
erlotinib
Resistant
:
C3
erlotinib
Resistant: C3 – Early Trials
erlotinib
Resistant
:
C3
KRAS G13D
Colorectal Cancer
KRAS G13D
Colorectal Cancer
RGX-202
Sensitive: C3 – Early Trials
RGX-202
Sensitive
:
C3
RGX-202
Sensitive: C3 – Early Trials
RGX-202
Sensitive
:
C3
KRAS G13D
Colorectal Cancer
KRAS G13D
Colorectal Cancer
bevacizumab + PCM-075
Sensitive: C3 – Early Trials
bevacizumab + PCM-075
Sensitive
:
C3
bevacizumab + PCM-075
Sensitive: C3 – Early Trials
bevacizumab + PCM-075
Sensitive
:
C3
KRAS G13D
Non Small Cell Lung Cancer
KRAS G13D
Non Small Cell Lung Cancer
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
KRAS G13D
Non Small Cell Lung Cancer
KRAS G13D
Non Small Cell Lung Cancer
ASTX029
Sensitive: C4 – Case Studies
ASTX029
Sensitive
:
C4
ASTX029
Sensitive: C4 – Case Studies
ASTX029
Sensitive
:
C4
KRAS G13D
Colorectal Cancer
KRAS G13D
Colorectal Cancer
LY3214996
Sensitive: D – Preclinical
LY3214996
Sensitive
:
D
LY3214996
Sensitive: D – Preclinical
LY3214996
Sensitive
:
D
KRAS G13D
Colon Cancer
KRAS G13D
Colon Cancer
cetuximab
Resistant: D – Preclinical
cetuximab
Resistant
:
D
cetuximab
Resistant: D – Preclinical
cetuximab
Resistant
:
D
KRAS G13D
Colorectal Cancer
KRAS G13D
Colorectal Cancer
MEN1611
Sensitive: D – Preclinical
MEN1611
Sensitive
:
D
MEN1611
Sensitive: D – Preclinical
MEN1611
Sensitive
:
D
KRAS G13D
Colorectal Cancer
KRAS G13D
Colorectal Cancer
BMS-754807
Resistant: D – Preclinical
BMS-754807
Resistant
:
D
BMS-754807
Resistant: D – Preclinical
BMS-754807
Resistant
:
D
KRAS G13D
Colorectal Cancer
KRAS G13D
Colorectal Cancer
cetuximab + vemurafenib
Resistant: D – Preclinical
cetuximab + vemurafenib
Resistant
:
D
cetuximab + vemurafenib
Resistant: D – Preclinical
cetuximab + vemurafenib
Resistant
:
D
KRAS G13D
Colorectal Cancer
KRAS G13D
Colorectal Cancer
sunitinib
Resistant: D – Preclinical
sunitinib
Resistant
:
D
sunitinib
Resistant: D – Preclinical
sunitinib
Resistant
:
D
KRAS G13D
Colorectal Cancer
KRAS G13D
Colorectal Cancer
trametinib + repotrectinib
Sensitive: D – Preclinical
trametinib + repotrectinib
Sensitive
:
D
trametinib + repotrectinib
Sensitive: D – Preclinical
trametinib + repotrectinib
Sensitive
:
D
KRAS G13D
Colorectal Cancer
KRAS G13D
Colorectal Cancer
ME-522
Sensitive: D – Preclinical
ME-522
Sensitive
:
D
ME-522
Sensitive: D – Preclinical
ME-522
Sensitive
:
D
KRAS G13D
Solid Tumor
KRAS G13D
Solid Tumor
adagrasib
Sensitive: D – Preclinical
adagrasib
Sensitive
:
D
adagrasib
Sensitive: D – Preclinical
adagrasib
Sensitive
:
D
KRAS G13D
Solid Tumor
KRAS G13D
Solid Tumor
sotorasib
Resistant: D – Preclinical
sotorasib
Resistant
:
D
sotorasib
Resistant: D – Preclinical
sotorasib
Resistant
:
D
KRAS G13D
Pancreatic Adenocarcinoma
KRAS G13D
Pancreatic Adenocarcinoma
ASN007
Sensitive: D – Preclinical
ASN007
Sensitive
:
D
ASN007
Sensitive: D – Preclinical
ASN007
Sensitive
:
D
KRAS G13D
Colorectal Adenocarcinoma
KRAS G13D
Colorectal Adenocarcinoma
ASN007
Sensitive: D – Preclinical
ASN007
Sensitive
:
D
ASN007
Sensitive: D – Preclinical
ASN007
Sensitive
:
D
KRAS G13D
Colorectal Cancer
KRAS G13D
Colorectal Cancer
SHR-A1307
Sensitive: D – Preclinical
SHR-A1307
Sensitive
:
D
SHR-A1307
Sensitive: D – Preclinical
SHR-A1307
Sensitive
:
D
KRAS G13D
Head and Neck Cancer
KRAS G13D
Head and Neck Cancer
SHR-A1307
Sensitive: D – Preclinical
SHR-A1307
Sensitive
:
D
SHR-A1307
Sensitive: D – Preclinical
SHR-A1307
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login